covid - 19 iibr updates you

Clinical trials for IIBR's vaccine will begin on Sunday, November 1st

​This is our vaccine's story from research to production

 

 

Introducing BriLife

​"Bri", alludes to the Hebrew word for health, "briut,", "iL" alludes to Israel, and "life" speaks to the importance of the vaccine. The name of the institute, IIBR is also hidden there with pride.​

 

 

Historic moment - IIBR's Covid-19 vaccine is underway

​An important milestone was completed.

In a process that took place at IIBR, 25,000 dosages of the COVID-19 vaccine, intended to be used in the clinical trials, have been prepared. Bottles, containing the vaccine, were filled with three batches (production series) in accordance to the needed dosages for the clinical trials. 

The vaccine safety and efficacy were proven in preclinical studies at IIBR.

The vaccine awaits final regulatory stages of the Ministry of Health.

Picture was taken at IIBR
 

 

Congratulations to Prof. Shapira - 2nd place on the list of 50 influential Jews for 2020

​Prof. Shmuel C. Shapira was awarded 2nd place on Jerusalem post's prestigious list of “50 influential Jews for 2020” for leading IIBR's efforts in developing its Covid-19 vaccine. 
 

 

Low feasibility for aerosol or indirect transmission from inanimate surfaces around COVID-19 patients

​To estimate the risk of SARS-CoV-2 transmission to humans by surface contact, we examined the stability of the virus on variety of surfaces, typical of urban environment or patient environment. We used PCR to detect the virus, tissue culture based growth test to determine virus viability and ability to infect new host. At room temperature, SARS-CoV-2 gradually loss its viability and decay completely at day 4. The decay rate increases at higher temperatures...............

Published: Clinical Microbiology and Infection​, 10 September 2020
 

 

PHD

Women In Science

0

Fields of scientific knowledge

Biology

IIBR leads na​tional efforts to counter any and all biological threats from intentional attacks as well as naturally-emerging diseases. Using a multi-disciplinary project strategy, combined with cutting edge technologies, we develop methods for the identification of various bio-threats; forensic investigation of bio-terror agents and pathogenesis mech​anisms; design of new strategies for vaccine development, as well as evaluation of novel modalities of therapeutics. IIBR biotechnology cGMP multi-product facility, is designed for the development and production of bio-pharmaceuticals and unique vaccines for national preparedness. ​

EXPLORE
 

Environmental science

IIBR research and development concerning environmental sciences ranges from numerical mod​eling to laboratory and field​​​​ experiments in the areas of meteorology and atmospheric contaminants. IIBR has developed capabilities that enable detection and identification of hazardous materials, weather and dispersion prediction, physical protection and evaluation of potential risks.

EXPLORE
 

Chemistry

Toxicological eval​uation at IIBR is followed by the generation of novel treatment protocols and drugs, rapid and effective solutions for damage prevention and control. These are g​ained by a combination of cutting-edge synthetic capabilities and an advanced analytical toolbox. All are based on comprehensive pharmacological and pathophysiological understanding and advanced experimental means.​

EXPLORE
 
Collaborate

Newsroom

Scientific Publications

​IIBR's latest Scientific Publications in the fields of biology, chemistry and the environmental sciences​.

read moreaboutScientific Publications

News

​Read about IIBR in the press.





read moreaboutNews